$HOTH NEW YORK, June 27, 2019 /PRNewswire/ -- Hoth Therapeutics, Inc. (HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, today announced that it has entered into a sponsored research agreement with the George Washington University (GW) to explore the potential use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.
